Search: WFRF:(Severin F. F.) > Clinical outcome en...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06562naa a2200853 4500 | |
001 | oai:gup.ub.gu.se/180384 | |
003 | SwePub | |
008 | 240528s2013 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:liu-99814 | |
024 | 7 | a https://gup.ub.gu.se/publication/1803842 URI |
024 | 7 | a https://doi.org/10.1093/eurjhf/hft0952 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-998142 URI |
040 | a (SwePub)gud (SwePub)liu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Zannad, F.u Université de Lorraine, Nancy, France4 aut |
245 | 1 0 | a Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document |
264 | c 2014-01-27 | |
264 | 1 | b Wiley,c 2013 |
520 | a Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g. all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 12-13 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the group's recommendations for achieving common views on heart failure endpoints in clinical trials. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a Heart failure | |
653 | a Morbidity | |
653 | a Mortality | |
653 | a Clinical trials | |
653 | a Heart failure | |
700 | 1 | a Garcia, A. A.u European Medicines Agency, Madrid, Spain4 aut |
700 | 1 | a Anker, S. D.u Charité Medical School, Berlin, Germany,Brigham and Women's Hospital, Boston, MA, USA4 aut |
700 | 1 | a Armstrong, P. W.u University of Alberta, Edmonton, Canada,Medical University, Military Hospital, Wroclaw, Poland4 aut |
700 | 1 | a Calvo, G.u Hospital Clinic of Barcelona, Spain4 aut |
700 | 1 | a Cleland, J. G.u Castle Hill Hospital, Kingston-upon-Hull, UK4 aut |
700 | 1 | a Cohn, J. N.u University of Minnesota, Minneapolis, USA4 aut |
700 | 1 | a Dickstein, K.u University of Bergen, Stavanger University Hospital, Norway4 aut |
700 | 1 | a Domanski, M. J.u Mount Sinai School of Medicine, New York, USA,University of Brescia, Italy4 aut |
700 | 1 | a Ekman, Inger,d 1952u Gothenburg University,Göteborgs universitet,Centrum för personcentrerad vård vid Göteborgs universitet (GPCC),University of Gothenburg Centre for person-centred care (GPCC),Sahlgrenska Academy, Gothenburg University, Sweden4 aut0 (Swepub:gu)xekmin |
700 | 1 | a Filippatos, G. S.u Athens University Hospital Attikon, Greece4 aut |
700 | 1 | a Gheorghiade, M.u Northwestern University Feinberg School of Medicine, Chicago, IL, USA4 aut |
700 | 1 | a Hernandez, A. F.u Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA4 aut |
700 | 1 | a Jaarsma, Tinyu Linköpings universitet,Hälsa, Aktivitet, Vård (HAV),Hälsouniversitetet4 aut0 (Swepub:liu)tinja77 |
700 | 1 | a Koglin, J.u Merck, Sharpe & Dohme Corporation, Whitehouse Station, NJ, USA4 aut |
700 | 1 | a Konstam, M.u Tufts University, Boston, MA, USA4 aut |
700 | 1 | a Kupfer, S.u Takeda Pharmaceuticals, Deerfield, IL, USA4 aut |
700 | 1 | a Maggioni, A. P.u ANMCO Research Center, Florence, Italy4 aut |
700 | 1 | a Mebazaa, A.u Hopital Lariboisiere, Paris, France4 aut |
700 | 1 | a Metra, M.u Hospital 12 de Octubre, Madrid, Spain,Amgen Inc., Thousand Oaks, CA, USA4 aut |
700 | 1 | a Nowack, C.u Bayer Pharma AG, Wuppertal, Germany4 aut |
700 | 1 | a Pieske, B.u Medical University of Graz, Austria4 aut |
700 | 1 | a Pina, I. L.u Montefiore Medical Center, Bronx, NY, USA4 aut |
700 | 1 | a Pocock, S. J.u London School of Hygiene and Tropical Medicine, UK4 aut |
700 | 1 | a Ponikowski, P.4 aut |
700 | 1 | a Rosano, G.u IRCCS San Raffaele Hospital, Rome, Italy4 aut |
700 | 1 | a Ruilope, L. M.4 aut |
700 | 1 | a Ruschitzka, F.u University Hospital Zurich, Switzerland4 aut |
700 | 1 | a Severin, T.u Novartis Pharma AG, Basel, Switzerland4 aut |
700 | 1 | a Solomon, S.4 aut |
700 | 1 | a Stein, K.u Boston Scientific Corporation, St. Paul, MN, USA4 aut |
700 | 1 | a Stockbridge, N. L.u Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA4 aut |
700 | 1 | a Stough, W. G.u Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA4 aut |
700 | 1 | a Swedberg, Karl,d 1944u Sahgrenska University, Hospital/Östra, Göteborg, Sweden4 aut0 (Swepub:gu)xsweka |
700 | 1 | a Tavazzi, L.u Villa Maria Cecilia Hospital, Cotignola, Italy4 aut |
700 | 1 | a Voors, A. A.u University Medical Center, Groningen, The Netherlands4 aut |
700 | 1 | a Wasserman, S. M.4 aut |
700 | 1 | a Woehrle, H.u ResMed, Ulm, Germany4 aut |
700 | 1 | a Zalewski, A.u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA4 aut |
700 | 1 | a McMurray, J. J.u University of Glasgow, UK4 aut |
710 | 2 | a Université de Lorraine, Nancy, Franceb European Medicines Agency, Madrid, Spain4 org |
773 | 0 | t European Journal of Heart Failured : Wileyg 15:10, s. 1082-1094q 15:10<1082-1094x 1388-9842x 1879-0844 |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1093/eurjhf/hft095 |
856 | 4 8 | u https://gup.ub.gu.se/publication/180384 |
856 | 4 8 | u https://doi.org/10.1093/eurjhf/hft095 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-99814 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view